Skip to main content
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Dyadic International, Inc. (DYAI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysisthe core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Dyadic International, Inc.

DYAI NASDAQ Categories PDF
Healthcare · Biotechnology
Jupiter, FL 33477-5094, United States IPO 2008 dyadic.com Updated Jul 15, 3:56am
Price
$1.21
Market Cap
$44.1M
Employees
5
Beta
1.15
Avg Volume
289,543
CEO
Mark A. Emalfarb

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.

Runs with full report
Price Overview
Last updated: Jul 15, 2026 5:46am (just now)
Current data · timestamped when a report runs
$1.21
Change · Jul 15
+0.19 (+18.63%)
Day Range
$1.01 – $1.34
52-Week Range
$0.65 – $1.35
50-Day MA
$0.79
200-Day MA
$0.89
Volume
771,923.00
Analyst Price Targets
Low $3.00
Consensus $3.00
High $3.00
(1 analysts)
Share Structure
Outstanding 36,438,700.00
Float 27,084,156.00
Free Float 74.3%
Normal free float — 74.3% of shares trade freely, ~25.7% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History
Please log in to view the price history chart
The interactive 5-year price chart is a members feature — accounts are free.
Log in
Revenue & Net Income Trend
Please log in to view the revenue & earnings trend
Statement visualizations are a members feature — accounts are free.
Log in
Key Metrics
Please log in to view key metrics & ratios
The full valuation-ratio breakdown is a members feature — accounts are free.
Log in
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Financial Statements
Please log in to view the financial statements
Income statement, balance sheet, cash flow, estimates & dividends tables are a members feature — accounts are free.
Log in
Insider Trading
Please log in to view insider transactions
The insider buy/sell ledger is a members feature — accounts are free.
Log in
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for DYAI — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for DYAI. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.423 · d5eed074 · 2026-07-14 21:04:01